Searchable abstracts of presentations at key conferences on calcified tissues

ba0005p123 | Cancer and bone: basic, translational and clinical | ECTS2016

The SRC kinase inhibitor saracatinib limits the development of osteolytic bone disease in multiple myeloma

Heusschen Roy , Muller Josephine , Binsfeld Marilene , Plougonven Erwan , Mahli Nadia , Carmeliet Geert , Leonard Angelique , Cohen-Solal Martine , Vanderkerken Karin , Beguin Yves , Menu Eline , Caers Jo

Destructive bone lesions due to osteolytic bone disease (OBD) are a major cause of morbidity and mortality in multiple myeloma (MM) patients and the development of new therapeutic strategies is of great interest. In this study, we assessed the effect of SRC inhibition with saracatinib (AZD0530, AstraZeneca) on the development of MM and its associated OBD. We first determined SRC family kinase expression in the MM microenvironment and found that myeloma cells express SRC at low...